Is AbbVie a Millionaire Maker?
(NYSE: ABBV) is an investment that is full of contradictions. It has a strong pharmaceutical business, but the third quarter of 2025 was terrible on the earnings front. It has an attractive 3% dividend yield, but it is near the low side of the historical yield range. Given the pros and cons, could buying AbbVie now help you build a million-dollar portfolio?
AbbVie is a pharmaceutical company. With a market cap of $400 billion, it is a substantial competitor in the industry. Its core focus is on immunology, oncology, neuroscience, and aesthetics. You may be familiar with some of its well-known brand-name drugs, including Humira and Botox. There's an interesting dichotomy here.
Image source: Getty Images.
Source Fool.com
AbbVie Inc. Aktie
177,10 €
-0,25 %
Die Aktie ist derzeit ein absoluter Favorit unserer Community mit 31 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung.
Ein leicht positives Kursziel von 210 € für AbbVie Inc. gegenüber dem aktuellen Kurs von 177.1 € wird gesehen.
